Insider · CIK 0001832671
Katherine Bach Kalin
Files at SLS (SELLAS Life Sciences Group, Inc.). First filing May 22, 2025, latest Nov 21, 2025.
Katherine Bach Kalin files SEC Form 4 as director at SLS (SELLAS Life Sciences Group, Inc.). Since May 22, 2025, Katherine Bach Kalin has reported 2 open-market buys worth $137k and 0 open-market sells worth $0, the latest filed on Nov 21, 2025.
A track record needs three past buys with six months of prices behind them; Katherine Bach Kalin has 0, so none is measured yet.
The newest scored trade: bought $101k of SLS on Nov 19, 2025, filed Nov 21, 2025, scored 35 (weak). In the last 12 months: 1 buy worth $101k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SLS: SELLAS Life Sciences Group, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | SLSbuy SELLAS Life Sciences Group, Inc. | $101k 63,400 shares | +155% | - | |
| 39Weak | SELLAS Life Sciences Group, Inc. | $36k 20,000 shares | +95% | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 7, 2026 | SLS SELLAS Life Sciences Group, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 154,400 | Jan 9, 2026 |
| Nov 19, 2025 | SLS SELLAS Life Sciences Group, Inc. | POpen-market purchase Common Stock | +63,400 | $1.59 | $101k | 104,400 | Nov 21, 2025 |
| May 22, 2025 | SLS SELLAS Life Sciences Group, Inc. | POpen-market purchase Common Stock | +20,000 | $1.80 | $36k | 41,000 | May 22, 2025 |
| Jan 10, 2025 | SLS SELLAS Life Sciences Group, Inc. | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 21,000 | Jan 14, 2025 |
| Jan 10, 2025 | SLS SELLAS Life Sciences Group, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jan 14, 2025 |
Questions about Katherine Bach Kalin
Answered from the filings on this page, as of the latest one.
Is Katherine Bach Kalin buying or selling?
In the last 12 months Katherine Bach Kalin reported 1 open-market buy worth $101k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $101k of SLS on Nov 19, 2025. Grants, option exercises and tax withholding are not counted.
How did Katherine Bach Kalin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Katherine Bach Kalin has 0.
Where does Katherine Bach Kalin file Form 4?
Katherine Bach Kalin has filed Form 4 at SLS (SELLAS Life Sciences Group, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.